Atypical choroid plexus papilloma treated with single agent bevacizumab

Francois G. Kamar,1,2 Victor F. Kairouz,3 Selim M. Nasser,1,2 Sami G. Faddoul,4 Ibrahim C. Saikali1,2
1Division of Hematology and Oncology, Clemenceau Medical Center, Beirut, Lebanon; 2Lebanese American University, School of Medicine, Byblos, Lebanon; 3Buffalo University, New York, NY, USA; 4Columbia University College of Physician and Surgeons, New York, NY, USA

Abstract

Choroid plexus papillomas (CPPs) are usually not malignant and occur in less than 1% of brain tumors in patients of all ages. They represent 3% of childhood intracranial neoplasms with a predilection in younger ages. Papillomas have an indolent course and carry a good long-term outcome if gross total surgical resection is achieved. However malignant evolution may occur, with a 10-30% incidence. Chemotherapy has been used with varied degrees of success. Most series are very small, some are only limited to case reports and cannot lead to guidelines or therapeutic recommendations. We are reporting the first case of recurrent CPP treated with 5 mg/kg of bevacizumab administered once every two weeks. Complete patient evaluations with follow-up contrast-enhanced magnetic resonance imaging (MRI) scans were obtained after the initial two treatments and every 8 weeks thereafter. Only after two treatments, the MRI scans showed radiological stabilization of the tumor, and the patient achieved an excellent clinical response with significant resolution of all skin lesions.

Introduction

Choroid plexus papillomas are usually indolent and occur in less than 1% of brain tumors in patients of all ages. They represent 3% of childhood intracranial neoplasms with a predilection in younger ages,12 70% occurring in children less than 2 years old.1,5 Choroid plexus tumors are graded based on the World Health Organization (WHO) classification scheme and include choroid plexus papilloma (CPP, WHO grade I), atypical choroid plexus papilloma (APP, WHO grade II), and choroid plexus carcinoma (CPC, WHO grade III).6 Papillomas have an indolent course and carry a good long-term outcome if gross total surgical resection is achieved.1 However, malignant evolution may occur, with a 10-30% incidence.2,7,8 Choroid plexus carcinomas are typically malignant, aggressive tumors that have 5-year survival rates reported to be around 40%.9

Histological appearance is not always predictive of biologic behavior. Some highly anaplastic choroid plexus tumors can be clinically benign, whereas some histologically inactive tumors are invasive.1,7,10,11 When malignant degeneration occurs, these tumors tend to behave like carcinomas and carry a dismal prognosis, with a 5-year survival rate of 26% (Figure 1).1,7,11

Adjuvant radiation therapy has been used in small series and reported to achieve acceptable long-term control when used in subtotal resected tumors.11,13

Case Report

A 40-year-old woman was referred to us for salvage treatment. She was diagnosed in February 2005 with a 6.5 cm right occipital tumor with small millimetric parenchymal metastases and drop metastases throughout the neuraxis. She presented with clinical evidence of increased intra-cranial pressure (ICP), mass effect with extensive vasogenic edema requiring urgent surgery. She underwent gross tumor resection and pathology reported an atypical choroid plexus papilloma. Her staging work up was obtained following her recovery including brain and full spine contrast enhanced magnetic resonance imaging (MRI) scans. This revealed small drop metastases in the posterior fossa and along the spinal cord. The patient received radiation therapy to the neuraxis (the CSI dose was 36 Gy and the total dose to the primary tumor bed or surgical cavity was 54 Gy). She remained clinically stable for two years, and was able to perform activities of daily living. Repeated contrast enhanced MRI scans of the brain and full spine reported stable appearance in size and enhancement of all drop metastases in the posterior fossa and the spinal canal.

At relapse, she presented with continuous headaches, neck stiffness, altered mental status, and severe ataxia. Imaging revealed metastasis to bilateral cerebello-pontine (CP) angles and intraparenchymal supratentorial lesions (left frontal, right thalamic, and right temporal). She received 2 cycles of nitrosourea without response and worsening symptoms. Hence this was changed to ifosfamide, carboplatin and etoposide based combination. Radiological and clinical stabilization were attained following three cycles, but second progression was documented after the fifth cycle. Further surgeries and performed for rapidly growing and symptomatic right CP angle metastasis and dorsal brain stem metastasis. Post-operative imaging revealed decrease size of the tumor. With remaining residual disease, the patient was referred to us for salvage treatment.

In this setting of previous craniospinal irradiation, significant chemotherapy toxicity, and only short-lived stabilization of the disease, bevacizumab was offered as single agent treatment in an attempt to spare the patient further toxicities. The first treatment was injected after 8 weeks from last surgery. The patient received bevacizumab, 5 mg/kg on day 1 and day 15 of each cycle. Cycles were repeated every 4 weeks. Contrast enhanced MRI scans were obtained after the initial two treatments and every 2 cycles thereafter or sooner if required to assess new or worsening symptoms.

The patient was taken off steroids, which was started at first relapse, shortly after starting bevacizumab and did not receive steroids later during the course of her disease. Her symptoms immediately stabilized following the first cycle of bevacizumab and progressively improved. The headaches resolved, the mental status returned to normal, and the ataxia improved very slowly but her cervical pain and stiffness did not. She achieved radiological stabilization with significant decrease of the vasogenic edema, and minimal decrease in the size and enhancement of all metastatic lesions (Figures 2 and 3). This response continued for over 5 months of therapy. A total of five cycles of bevacizumab were administered (10 treatments). An elective cerebello-pontine angle
metastasis resection was opted to relieve her debilitating neck stiffness.

The postoperative course was complicated by respiratory failure requiring tracheostomy, although there was no evidence of disease progression. The patient died from pulmonary infection, in turn complicated by severe sepsis.

Discussion

Choroid plexus tumors typically grow within the choroid plexus tissue. A gross total resection is thought to be curative in CPP. Recurrences are infrequent and the prognosis is good.14 APPs represent a novel intermediate-grade subtype of CPT. Its clinical features and treatment outcomes have not been well established in the literature. Several studies have suggested that adjuvant therapy, radiation alone, or radiation along with chemotherapy decreases the incidence of local recurrence and improves long-term survival.15-17

Chemotherapy has been used with varied degrees of success. Pediatric protocols combining cisplatin and etoposide;2 cyclophosphamide, cisplatin and Vincristine12 ifosfamide, carboplatin and etoposide,19 or more complex regimens,13 such as the POG (alternating courses of cisplatin/etoposide and cyclophosphamide/vincristine, followed by radiation).12 Nevertheless most series are very small, some are only limited to case reports and cannot lead to guidelines or therapeutic recommendations.

In this particular case, two lines of chemotherapy had failed, and poor marrow reserve secondary to craniospinal radiotherapy in an adult patient (36 Gy of craniospinal irradiation and 54 Gy to the cranium) prevented further delivery of cytotoxics. Furthermore she has received and failed two chemotherapy lines: single agent nitrosourea and combination of ifosfamide, carboplatin and etoposide.

Experts characterized CCPs with extraordinary degree of vascularity.19 Recent pathological findings identified most Atypical CCP to be highly vascularized lesions.20 In addition to the vascularized nature of CCPs, the choice of therapy was based on the widely disseminated disease and the extensive vasogenic edema requiring high doses of steroids to maintain a good quality of life. Moreover, the lack of significant toxicities of bevacizumab made it somehow attractive. This option was discussed with the patient, who signed an informed consent, and was approved by the ethical committee of our institution.13

A lengthy literature search did not yield any case of choroid plexus tumors treated with bevacizumab; we are reporting the first case. Although there was only minimal radiological improvement, bevacizumab seems to have
some activity in this subtype of richly vascularized tumors and may be worth further evaluation in combination with chemotherapy.

**Conclusions**

Single agent bevacizumab has achieved stabilization of the disease during the 5 months of therapy and three months later on off therapy. Cases of CPTs are scarce and there are no treatments guidelines. A multicenter collaborative trial combining bevacizumab to chemotherapy may be worth further evaluation for CPTs earlier during the treatment course.

**References**